CCL19

CCL19 Molekülinformation

Englischer Name	C-C motif chemokine 19	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1	Target-Alias	Beta-chemokine exodus-3，CK beta-11，Epstein-Barr virus-induced molecule 1 ligand chemokine，EBI1 ligand chemokine，ELC，Macrophage inflammatory protein 3 beta，MIP-3-beta，Small-inducible cytokine A19，MIP3B，SCYA19
Höchste Forschungs- und Entwicklungsphase	Phase 1 Clinical

Englischer Name	C-C motif chemokine 19
Target-Alias	Beta-chemokine exodus-3，CK beta-11，Epstein-Barr virus-induced molecule 1 ligand chemokine，EBI1 ligand chemokine，ELC，Macrophage inflammatory protein 3 beta，MIP-3-beta，Small-inducible cytokine A19，MIP3B，SCYA19
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Phase 1 Clinical

CCL19 Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
Tag Free (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
CC9-H5215	Human	HEK293	Human CCL19 / MIP-3 beta Protein, Tag Free (HPLC verified)				In den Warenkorb legen

Gesamtmenge1

CCL19 Molekülhintergrund

C-C motif chemokine 19(CCL19) is as known as CK beta-11, ELC, MIP3B and SCYA19. May play a role not only in inflammatory and immunological responses but also in normal lymphocyte recirculation and homing. May play an important role in trafficking of T-cells in thymus, and T-cell and B-cell migration to secondary lymphoid organs. Binds to chemokine receptor CCR7. Recombinant CCL19 shows potent chemotactic activity for T-cells and B-cells but not for granulocytes and monocytes. Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4.

CCL19 Molekülalias

CCL19,MIP-3 beta,MIP-3-beta,ELC,MIP3B,SCYA19,EBI1 ligand chemokine

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine)		Phase 1 Clinical	Guangdong Zhaotai Invivo Biomedicine Co Ltd, Hunan Zhaotai Yongren Biotech Co Ltd	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung	Details